CME
HOME SITEMAP REGISTRATION FEEDBACK ALL COURSES MY CME

Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer

TEST_code
CME Activity Information
Release Date: February 12, 2007
Most Recent Review: February 12, 2007*
Most Recent Update: February 12, 2007
Date Credit Expires: February 12, 2009
Time to Complete: 1 hour
Medium: Internet Online
*Click here to learn more about our review process.
Instructions for Participation

  1. Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
  2. Study the educational activity
  3. Complete the CME quiz and evaluation
  4. After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

    *The CME quiz and evaluation must be completed by February 12, 2009, in order to receive the credit or participation certificate.

 

Target Audience
Physicians who wish to advance their current knowledge of clinical cancer medicine in lung cancer and are involved in providing patient care in a cancer care environment.

Learning Objectives
After completing this course, the reader should be able to:
  1. Describe the molecular mechanisms of action, safety profile, rationale for NSCLC treatment, and main current evidence in NSCLC treatment using the multi-kinase inhibitors sorafenib and sunitinib.
  2. Summarize the main clinical trials performed with sorafenib and sunitinib in the treatment of solid tumors.
  3. Describe the clinical trials performed with sorafenib and sunitinib in NSCLC and suggest the future clinical development of these two drugs in the treatment of NSCLC.
Accreditation and Credit Designation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the National Institutes of Health Foundation for Advance Education in the Sciences (NIH/FAES) and The Oncologist. The NIH/FAES is accredited by the ACCME to provide continuing medical education for physicians.

The NIH/FAES designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy
In compliance with the Standards of the ACCME, it is the policy of the NIH/FAES to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities and to include information free of commercial bias and based on the best evidence available. All individuals in a position to influence the content of this activity have disclosed relevant financial interests or relationships of their own, their spouse/partner, or their worksite, with manufacturers or providers of commercial products, services, technology, or programs; and disclosed relationships with current non-governmental supporters of the activity. The faculty and planners have indicated that they have no relevant commercial relationships. For a list of the faculty and planners, please visit the Editorial Board online at http://cme.theoncologist.com/misc/edboard.shtml.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process: http://theoncologist.alphamedpress.org/misc/ifora.shtml. All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Author Disclosure(s)
Cesare Gridelli, M.D.

Credentials: Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy. Telephone: +39-0825-203573; Fax: +39-0825-203556; E-mail: cgridelli{at}libero.it.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Pfizer's sunitinib and Bayer's sorafenib for non-small cell lung cancer.

Paolo Malone, M.D.

Credentials: Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Pfizer's sunitinib and Bayer's sorafenib for non-small cell lung cancer.

Filomena Del Gaizo, M.D.

Credentials: Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Pfizer's sunitinib and Bayer's sorafenib for non-small cell lung cancer.

Giuseppe Colantuoni, M.D.

Credentials: Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Pfizer's sunitinib and Bayer's sorafenib for non-small cell lung cancer.

Ciro Guerriero, M.D.

Credentials: Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Pfizer's sunitinib and Bayer's sorafenib for non-small cell lung cancer.

Carmine Ferrara, M.D.

Credentials: Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Pfizer's sunitinib and Bayer's sorafenib for non-small cell lung cancer.

Dario Nicolella, M.D.

Credentials: Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Pfizer's sunitinib and Bayer's sorafenib for non-small cell lung cancer.

Daniela Comunale, M.D.

Credentials: Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Pfizer's sunitinib and Bayer's sorafenib for non-small cell lung cancer.

Alba De Vita, M.D.

Credentials: Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Pfizer's sunitinib and Bayer's sorafenib for non-small cell lung cancer.

Antonio Rossi, M.D.

Credentials: Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Pfizer's sunitinib and Bayer's sorafenib for non-small cell lung cancer.

Commercial Support
Non-governmental supporters of this activity: AstraZeneca, Bristol-Myers Squibb Oncology, and sanofi-aventis

Hardware/Software Requirements
The Oncologist CME Online supports the following browsers: Current production versions of Opera, Safari, Firefox, Lynx and Mozilla; Netscape 6.1 and above, and Explorer 6.0 and above. The Macintosh version of Explorer was discontinued in June 2003, and is not supported.

Other Links
Disclaimer
Privacy statement

Correspondence
The Oncologist CME Online
c/o AlphaMed Press
318 Blackwell Street, Suite 260
Durham, North Carolina 27701
Phone: (919) 680-0011
Fax: (919) 680-4411
Email: angela.davies{at}ucdmc.ucdavis.edu

HOME SITEMAP REGISTRATION FEEDBACK ALL COURSES MY CME
Copyright © 2008 by AlphaMed Press.